Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

A legfontosabb adatok

Ki végzi
Contineum Therapeutics
Hol
Duncansville, Hartsdale, Marietta, Phoenix és Salt Lake City (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
43 fő vett részt
Kezdés
2025. febr. 4.
Befejezés
2026. jan. 20.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • PIPE-791
  • Placebo
A regiszteradat frissítve
2026. március 18.

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female 18 to 70 years of age, inclusive, at the first Screening visit
  • Only one of the following chronic pain diagnoses at least 6 months prior to Screening:
  • Osteoarthritis of the knee OR low back pain (with or without painful lumbosacral radiculopathy)
  • Plain radiographs of the knee or lumbar spine consistent with diagnosis within 9 months prior to or during Screening
  • History of related daily pain for at least 6 months prior to Screening
  • Have a body mass index <40 (inclusive) at Screening
  • Willing to maintain a consistent regimen of any ongoing (stable format and frequency for the duration of study participation) non-pharmacologic pain-relieving therapies
  • Willing to discontinue medications taken for chronic pain conditions and usage of transcutaneous electrical nerve stimulation for the duration of the study
  • Male or female subjects with reproductive potential agree to comply with a highly effective contraceptive method as per protocol through 90 days after last study drug administration
  • Subjects taking systemic hormone-replacement therapy must be on a stable dose and regimen for at least 1 month prior to Screening
  • General good medical health with no clinically significant or relevant abnormalities except those attributed to the underlying chronic pain condition, including medical history, physical exam, vital signs, ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator
  • Ability to use an eDiary to record daily pain scores

Ki nem vehet részt

  • Concurrent diagnosis of fibromyalgia or evidence of chronic widespread pain, or other pain that may interfere with the assessment of CLBP or COAP
  • Received capsaicin treatment (e.g., Qutenza) within the past 3 months prior to screening
  • History of prior lumbar or thoracic spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion)
  • History of refractory chronic pain after multiple failed treatments as determined by the Investigator (e.g., no response to all of the following: surgery and/or nerve blocks, a regimen of at least two non-opioid pharmacotherapies, and physical rehabilitation, and weak opioids)
  • Have surgery planned during the study for any reason, related or not, to the disease state under evaluation
  • History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis
  • Diagnosed with OA during childhood or adolescence, including post-traumatic OA or OA due to genetic (e.g., hip dysplasia) or congenital (e.g., metabolic disorders) conditions
  • History of or clinical signs or symptoms of active joint infection, crystal disease of the knee, or a history of arthritis due to crystals (e.g., gout, pseudo gout)
  • Demonstrated noncompliance recording daily Numerical Rating Scale (NRS) scores during Screening
  • Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest, e.g., an ablation procedure
  • Are non-ambulatory (use of assistive devices is allowed)

Helyszínek itt: Egyesült Államok

  • Altoona Center of Clinical ResearchDuncansville, Egyesült ÁllamokNo longer taking part
  • Drug Trials AmericaHartsdale, Egyesült ÁllamokNo longer taking part
  • Drug Studies AmericaMarietta, Egyesült ÁllamokNo longer taking part
  • Arizona Research CenterPhoenix, Egyesült ÁllamokNo longer taking part
  • JBR Clinical ResearchSalt Lake City, Egyesült ÁllamokNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP.

A teljes eredeti leírásKevesebb

Subjects will:

* Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.

A vizsgálat 2 csoportja

  • Active followed by PlaceboA vizsgált kezelés

    Kezelés: PIPE-791 és Placebo

  • Placebo followed by ActiveA vizsgált kezelés

    Kezelés: PIPE-791 és Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Crossover Multicenter Study to Explore the Safety and Efficacy of Oral PIPE-791 as Treatment in Subjects With Chronic Osteoarthritis Pain (COAP) or Chronic Low Back Pain (CLBP)
Publikációk
A regiszteradat frissítve
2026. március 18.